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sources. Although experimental biological research is progressing steadily towards future clinical application, data on functionality, safety and efficiency of (human) artificial gametes are still preliminary. Although defining artificial gametes by startand end-points limited the number of included studies, the search resulted in a clear overview of the subject. Clinical use of artificial gametes would expand the treatment possibilities of MAR and would have implications for society. Before potential clinical use, the societal and ethical implications of artificial gametes should be reflected on.
INTRODUCTION
Estimates of the 12-month prevalence rate of infertility range from 3 to 17% in more developed nations, where more than half of the couples confronted with infertility seek medical help 1 . Reproductive medicine is currently able to help only 70% of the couples to deliver a child within 5 years after visiting a fertility clinic while relying on either patients' own or donor gametes 3 . Donor gametes are used in the case of failed homologue treatment and are the only current treatment option for patients without functional gametes, which includes men with non-obstructive azoospermia (0.63% of the general population; 42 ) and women with premature ovarian insufficiency (0.9% of the general population; 43 ). Moreover, gay couples are relying on donor gametes. Unfortunately, the current use of donor gametes does not lead to genetic parenthood, which is valued by most couples, although its objective importance is currently debated 44, 45 .
A potential future treatment alternative to using donor gametes is the use of socalled 'artificial gametes', i.e. gametes generated by manipulation of their progenitors or of somatic cells, which would allow children who are genetically related to both their parents to be conceived. The possibility of full genetic parenthood could also apply to gay couples, if reprogramming to the other sex germ line becomes an option, and to women of post-menopausal age.
Although the potential use of artificial gametes in medically assisted reproduction (MAR) has led to scientific and societal discussion, a systematic overview of the biological progress towards clinical application is lacking. This systematic review aimed to provide insight into the biological progress on all biological plausible routes to create artificial gametes in animals and humans, without evaluating quality, quantity and safety of the different approaches, which are currently unknown.
METHODS

Search strategy
The electronic database MEDLINE was systematically searched with the search engine PubMed using the following medical subject heading terms (MeSH-terms): 'cell differentiation', 'cells, cultured', 'cell culture techniques', 'cytoplasm/transplantation', 'diploidy', 'DNA, mitochondrial', 'embryonic stem cells', 'embryo transfer', 'female', 'fertilization', 'genotype', 'germ cells', 'germ cells/cytology', 'haploidy', 'human reproduction, assisted', 'meiosis', 'microinjections', 'micromanipulaton', 'nuclear transfer techniques', 'oocytes', 'oocytes/cytology', 'oocytes/physiology', 'oocytes/transplantation', 'oogenesis', 'oogonia/cytology', 'pluripotent stem cells', 'pregnancy', 'pregnancy outcome', 'reproductive techniques, assisted/ethics', 'reproductive techniques/ethics', 'spermatogenesis', 'spermatogonia/cytology', 'spermatozoa/cytology', 'stem cells/cytology' and 'stem cells/metabolism'. The reference lists of the eligible articles were subsequently hand searched (i.e. snowball strategy).
Article selection
Articles reporting on artificial gametes, published in English between January 1970 and December 2013, were considered for inclusion by screening their titles, abstracts and if necessary full-text reports.
Only studies reporting on originally collected biological data were considered, while reviews, opinion studies and other non-original work were excluded. Furthermore, studies needed to report on specific biological starting and end-points, which were defined a priori.
As starting points, i.e. cells that in a clinical application would be derived from the patient, adult GSCs and differentiated somatic cells were defined.
Adult GSCs with the reported capacity of migration to the stem cell niche in vivo after (xeno)transplantation (male GSCs) or proof of survival in vivo after (xeno)transplantation (female GSCs) were included as starting points. For the purpose of this review, we exclude the use of primordial germ cells, which, although they too are GSCs, cannot be retrieved from an adult commissioning parent and are thus not clinically relevant as starting point of treatment.
Differentiated somatic cells could be a starting point for artificial gamete formation in three ways.
First, artificial gametes could be formed from differentiated somatic cells via embryonic stem cells (ESCs). For clinical application, this would require somatic cell nuclear transfer of a patient nucleus into a donor ESC 46, 47 ; in this way, the ESCs contain the commissioning parent's genetic material. For the purpose of this review, however, ESCs as starting point of preclinical research were accepted for inclusion.
Second, artificial gametes could be formed from differentiated somatic cells via induced pluripotent stem cells (iPSCs). Articles that have iPSCs as starting point or use somatic cell reprogramming by ectopic expression were also included.
Third, artificial gametes could be formed from differentiated somatic cells by 'direct' differentiation into gametes without the occurrence or documentation of our defined The following end-points were defined: artificial gamete formation, fertilization and birth of offspring.
For males, the formation of artificial gametes was defined as: the presence of haploid male sperm cells, as proven by DNA content analyses or similar techniques and/or the presence of post-meiotic markers. This does not include sperm morphology, motility and fertilization potential without the use of ICSI. For females, artificial gamete formation was defined as: the presence of metaphase II secondary oocytes proven by DNA content analyses, meiotic markers and/or polar body extrusion. This does not include epigenetic normality and developmental potential, for example, to, or past, the blastocyst stage. These conditions were chosen for the review as they describe gametes which could be used for MAR, yet they are not necessarily genetically and epigenetically equal to normal gametes with respect to quality and developmental potential. They will therefore all be referred to as artificial sperm or artificial oocytes.
Fertilization was defined as the presence of a zygote with two pronuclei or a cleavage-stage embryo in which donor-derived DNA is detected.
Birth of offspring was defined as the birth of one or more viable offspring, in which donor-derived DNA is detected. Therefore, for example, studies that reported on spermatogenesis until the stage of the first meiotic division were excluded, as they did not achieve one of the three predefined end-points.
Meta-synthesis
Data were extracted using standardized data extraction sheets. Given the nature of the collected data, meta-synthesis, rather than meta-analyses was performed. The meta-synthesis was performed by two reviewers, independently, who discussed until consensus was met. In this way, the chance of a human error in classification or interpretation was reduced.
To structure the abundance of biological data, three strategies were used.
First, data were organized by the sex of the animal or commissioning parent whose genetic material was used (male or female) and by the type of artificial gamete that was formed (sperm or oocyte). More specifically, besides artificial generation of sperm from a male and of oocytes from a female, theoretically, it could be possible to create artificial sperm from a female and artificial oocytes from a male. Clinically, the latter could be relevant for gay couples wishing to have a child that is genetically related to both of them, instead of having to rely on donor gametes. Second, nine biologically plausible routes of artificial gamete generation were defined based on insight in the literature and clinically available cell types, as described in Figures 1 and 2 . Of the nine routes, two routes (Routes 1 and 2; the nature of Route 2 is exemplified in Figures 1 and 2 ) start from adult GSCs of the animal or commissioning parent whose genetic material will be used. Adult GSCs are spermatogonial stem cells (SSCs) or oogonial stem cells (OSCs), which would have to be retrieved from, respectively, the testis or ovary of the animal or commissioning parent whose genetic material will be used. The other seven routes (Routes 3 -9) start from a somatic cell of the animal or commissioning parent.
Four routes starting from a somatic cell (Routes 3 -6) require either ESCs (Routes 3 and 4) or iPSCs (Routes 5 and 6; the nature of Route 5 is exemplified in Figures  1 and 2) as transitional cell types. To generate transitional ESCs, the nucleus of an ESC of a donor embryo has to be replaced by the nucleus of a somatic cell from the animal or commissioning parent 46, 47 , while iPSCs result directly from reprogramming somatic cells from the animal or commissioning parent 48, 49 .
In the remaining three routes starting from somatic cells, artificial gametes are formed without a documented intermediate stage: somatic cell transformation into gametes without transitional cell types (Routes 7 and 8) and haploidization by transplantation of a somatic cell nucleus into an enucleated donor oocyte (Route 9), in which the somatic cell nucleus of the commissioning mother is injected into an enucleated (donor) oocyte, which by division induces haploidization of the somatic nucleus.
Third, for each potential route of artificial gamete generation, clinical applications are specified, as shown in Table I . For the treatment of heterosexual couples (or infertile singles relying on material from a healthy donor instead of a partner), eight routes are biologically plausible to result in artificial sperm from a male, whereas nine routes are biologically plausible to result in artificial oocytes from a female. The routes for which GSCs are the starting point obviously cannot be used for patients whose gonads do not contain GSCs.
For the treatment of gay couples, five routes might theoretically result in artificial oocytes from males, and six routes may result in artificial sperm from females.
Data were extracted for each of the nine plausible routes of artificial gamete formation based on the achievement of the farthest of the following end-points: artificial gamete formation, fertilization and birth of offspring. This review reports only on the farthest end-point reached, because of clinical relevance and because fertilization). Achievements from animal and human research were differentiated and the type of animals examined was specified.
RESULTS
Search strategy
The systematic search yielded 2424 articles (Figure 3 ). Based on eligibility, 46 studies were included. Hand searches of the reference lists of these studies, resulted in the inclusion of 24 additional studies. Thus, in total, 70 studies were included. Table I reports on the most advanced end-points achieved in animals and humans of all nine biologically plausible routes for the formation of artificial sperm.
Meta-synthesis
Artificial sperm from a male
Of the eight biologically plausible routes leading to the formation of artificial sperm from a male (Figure 1 ), seven were reported in literature as achieving at least one of the specified end-points in animals and/or humans (Table I) . In animal research, for one route (Route 5), the formation of artificial sperm was achieved as the most advanced end-point, while for six routes (Routes 1, 2, 3, 4, 6 and 8), one or more studies reported the birth of viable offspring. In humans, only two of the biologically plausible routes to artificial gamete formation (Routes 3 and 5) actually led to the generation of artificial sperm. In humans, no studies reported on fertilization or the birth of offspring.
In vitro differentiation of SSCs
In vitro culture and differentiation of SSCs resulted in artificial sperm in cattle 50 . Birth of offspring was achieved in mice 51 .
In vitro proliferation of SSCs followed by (auto)transplantation
In vivo haploidization after in vitro proliferation of SSCs resulted in the formation of artificial sperm in mice 52,53 and rats
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. Fertilization was reported in hamsters 55 . Birth of offspring was reported in mice 49, [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] , rats 54, 68, 69 and zebrafish
70
.
In vitro differentiation of ESCs
In mice, this route resulted in fertilization [71] [72] [73] . In one report, the birth of offspring was reported 74 . Human artificial sperm, expressing post-meiotic markers and/or haploidization attested by RNA expression analyses and DNA content analysis, respectively, has been generated from ESCs 5, 6, [75] [76] [77] .
In vitro differentiation of ESCs followed by autotransplantation
In mouse studies, in vitro differentiation of ESCs followed by autotransplantation resulted in the formation of artificial sperm 78 and the birth of offspring [79] [80] [81] [82] .
In vitro differentiation of iPSCs
Artificial sperm cells were created by in vitro iPSC differentiation in mice
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. Human artificial sperm was also created by in vitro differentiation of iPSCs 6, 75, 84 , some of which revealed incomplete imprinting 84 .
In vitro differentiation of iPSCs followed by autotransplantation Differentiating iPSCs in vitro followed by autotransplantation resulted in the formation of artificial sperm in mice 85 . Mouse offspring were born from iPSCs that .
In vitro somatic cell transformation into sperm without documented intermediate cell types
No studies achieving artificial sperm formation, fertilization or birth of offspring via this route were identified.
In vivo somatic cell transformation into sperm without documented intermediate cell types
Injection of mesenchymal stem cells into rats, previously sterilized by busulfan treatment, led to fertility and live births 86 .
Artificial oocytes from a female
Of the nine biologically plausible routes to artificial oocyte formation from a female (Figure 2 ), seven achieved at least one of the specified end-points in animals and/or humans (Table I) . In animal research, as the most advanced end-point, formation of animal artificial oocytes was achieved via three routes (Routes 1, 7 and 8), fertilization via one route (Route 9) and the birth of offspring was achieved via three routes (Routes 2, 3 and 5). In humans, four routes (Routes 1, 2, 3 and 7) achieved the formation of artificial oocytes as farthest end-point and one route (Route 9) resulted in fertilization.
In vitro differentiation of OSCs
Both mouse and human female germ stem cells have undergone meiosis in vitro, resulting in artificial oocytes 87 .
In vitro proliferation of OSCs followed by (auto)transplantation
After proliferation in vitro, mouse OSCs were transplanted to ovaries of recipient mice and the resulting artificial oocytes could be fertilized 87 and, in another study, contributed to the birth of offspring 88 . Human OSCs were proliferated in vitro and transplanted to human ovary tissue xenografted into mice, resulting in the formation of artificial oocytes 87 .
In vitro differentiation of ESCs
Starting with ESCs, in vitro differentiation led to the formation of artificialoocytes in mice but did not result in viable embryos or offspring so far 73, [89] [90] [91] . Offspring were born in mice by differentiating iPSCs into PGCLCs that formed aggregates in culture that, after being graftedunder the ovary bursa, formed mature artificial oocytes under in vivo-likeconditions 92, 93 . In humans,follicle-like structures were formed, but no oocytes with zona pellucidawere identified 5 .
In vitro differentiation of ESCs followed by testicular transplantation
No studies achieving artificial oocyte formation, fertilization or birth of offspring via this route were identified.
In vitro differentiation of iPSCs
Offspring were born in mice by differentiating iPSCs into PGCLCs that formed aggregates in culture that, after being grafted under the ovary bursa, formed mature artificial oocytes under in vivo-like conditions 92, 93 .
In vitro differentiation of iPSCs followed by autotransplantation
In vitro somatic cell transformation into oocytes without documented intermediate cell types
Somatic cells were shown to develop into artificial oocytes starting from rat pancreatic stem cells 94 and porcine skin stem cells 95 with uncharacterized genomic integrity andepigenetic status. In humans, amniotic stem cells differentiated in vitrointo artificial oocytes with unknown ploidy status and a diameter of50-60 mm 96 and a hepatic cell line differentiated in vitro into artificial oocytes, of which some spontaneously activated and developed germ cell/embryonic tumours in vivo 97 .
In vivo somatic cell transformation into oocytes without documented intermediate cell types
Mouse bone marrow transplants were shown to lead to the formation of artificial oocytes containing the genetic material of the donor. These oocytes, however, failed to lead to offspring 98, 99 . No studies described the achievement of the specified end-points using human cells.
Haploidization by transplantation of a somatic cell nucleus intoan enucleated donor oocyte
Artificial oocytes were formed by injecting somatic cell nuclei into enucleated (donor) oocytes. Although usually with low efficiency and unknown imprinting patterns, this induced haploidization of the somatic nucleus in mice 100-105 and rabbits 106 . Fertilization achieved after haploidization was infrequent and the development of embryos into 2-cell and blastocyst stages was reported without further knowledge about their developmental potential 107 . Haploidization by transplantation of a somatic cell nucleus into an enucleated donor oocyte also resulted in human artificial oocytes 103,108 that could be fertilized by ICSI 104, 109, 110 .
Artificial oocytes from a male
Of the nine biologically plausible routes that could theoretically lead to the formation of artificial oocytes from a male (Figure 1 ), one (Route 3) was reported in literature as achieving at least one of the specified end-points in animals and/or humans (Table I) . Artificial mouse oocytes were derived from male ESCs in vitro 89 . Male mouse ESCs differentiated in vitro into both artificial sperm and artificial oocytes. While being cultured in the same Petri dish, these artificial oocytes were fertilized (parthenogenetically) by the artificial sperm cells from the same ESC donor 72 . No studies described the achievement of the specified end-points using human cells.
Artificial sperm from a female
Of the nine biologically plausible routes leading to the formation of artificial sperm from a female (Figure 2 ), three were reported in literature asachieving at least one of the specified end-points in animals and/orhumans ( Table I ). The injection of a mouse cumulus cell into a mouseoocyte resulted in fertilization and embryos with chromosomal abnormalities 111 ; Route 8;
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). A variation to method nine (i.e. haploidization by transplantation of somatic cell nucleus into an enucleated donor oocyte), namely serial nuclear transfer of an oocyte nucleus (of Mother 1) into enucleated donor oocytes, could generate an 'imprint-free' oocyte from genetically manipulated females, which once injected into a final (nucleated) oocyte (of Mother 2), resulted in the birth of viable mice [113] [114] [115] . In the latter case, the offspring had a different phenotype (longevity) from the donor 113 . Haploid artificial sperm was formed by differentiating female human iPSCs, although the authors specifically refer to their incorrect or unknown epigenetic status (Route 5; 84 ).
DISCUSSION
This systematic review on the biological progress on artificial gametes towards clinical use is relevant to all MAR professionals. Previous reviews on artificial gametes 116-118 were narrative rather than systematic and did not include all studies identified by our extensive search.
Our overview of biological progress documents important advances in the formation of artificial gametes in animals and in humans. The ultimate proof that artificial gametes were generated is the birth of normal healthy offspring. The birth of animal offspring has been achieved using several methods, and although longterm safety has not been unambiguously proven, animal models thus provide a proof of principle that artificial gametes can be generated. The birth of animal offspring has been proven for both the generation of artificial sperm from a male and the generation of artificial oocytes from a female starting from both ESC and iPSCs. Additionally, animal offspring have been born using artificial sperm from females starting from somatic cells (via iPSCs and without documented intermediate stages) and oocytes.
To date, no study has reported the birth of human offspring from artificial gametes. The creation of human sperm from males was reported for two of the eight biologically plausible routes, but fertilization was not reported. The creation of human oocytes from females was reported for four of the nine biologically plausible routes and one route even resulted in fertilization. Human and/or animal research more often focused on creating artificial sperm (n=41) than on creating artificial oocytes (n=27). Research less often focused on creating artificial gametes from the opposite sex of the animal or commissioning parent than on creating artificial gametes from the same sex (i.e. 8/70 versus 66/70, respectively; of note, three studies reported on both). In humans, artificial sperm from a female was created, but fertilization was not reported. The shortage of research on creating artificial gametes from the opposite sex might, amongst others, be due to the following factors: (i) technical challenges (e.g. it is more challenging to develop oocytes from males than spermatozoa from males 30 ) that are imposed by the biological nature of male and female cells (e.g. sex-specific differences in the meiotic processes 119 ); (ii) less presumed demand from gay couples than from infertile heterosexual couples and (iii) less societal acceptance 120 .
Clearly, the full range of findings, including both the results that have been reported (e.g. birth of mice offspring) and the results that have not (yet) been reported (e.g. birth of children), is crucial to understanding the level of progress of the field. The functionality of human artificial gametes, the chromosomal and epigenetic stability of animal and human artificial gametes, and the viability and long-term health of artificial gamete-derived offspring have not been unambiguously proven. Furthermore, many findings are yet to be validated, by different research groups repeating the experiments and enhancing the efficiency of the techniques. Accordingly, the findings presented here should be considered as preliminary data, opening up new avenues for research that may eventually lead to clinical applications of artificial gametes. The pace of scientific progress and, with that, the timeframe for any potential future clinical application of artificial gametes, is difficult to predict 30 .
The systematic rather than narrative approach in this review has resulted in a complete overview of the current literature. The unconventional broad focus of our review, although relevant for MAR health care professionals, required overcoming several challenges.
First, the search strategy had to be very broad to identify articles covering different novel techniques, which are generally poorly indexed. We therefore used the snowball strategy to identify about one-third of our studies that were not in our initial search but were mentioned in the initially included studies.
Second, risk of bias in the included studies was not assessed, as no setsof quality criteria are available for biological proof-of-concept studies oropinion studies.
Initially, we attempted to develop a set of quality criteriafor biological proof-ofconcept studies, but this resulted in a very limitednumber of quantifiable and reproducible quality criteria, which did notcover the entire quality of the studies.
For example, specifying certainmarkers to be used or validation of gamete morphology assessmentswere not considered objective enough. Identifying quality criteria for biological proof-of-concept studies remains a challenge. We therefore did not exclude any of the studies meeting our predefined inclusion criteriaand end-points for means of fairness. This review synthesizes all that hasbeen reported, including methods that seem controversial at the moment. More specifically, (i) some groups 121, 122 doubt the presence of OSCs that have been reported by others (a.o. 87 ); (ii) some groups doubt the biological plausibility of haploidization by transplantation of a somatic cell nucleus into an enucleated donor oocyte 105 reported by others 104, 109, 110 and there is controversy on whether bone marrow cells can contribute to the formation of female germ cells 123 . As we refrain from assessing the quality of the individual studies cited in the absence of objective bias assessment criteria, we need to consider alternatives. The number of references (ideally from different research groups) for each end-point mentioned in Table I reflects reproducibility, which is an important quality criterion in biological studies.
Third, some critical remarks on the three predefined end-points (artificial gamete formation, fertilization, the birth off offspring) chosen for this review should be made. These end-points do not merely reflect phases in the process of the use of artificial gametes, but also reflect different levels of proof of functionality, in which the birth of offspring is the only real proof while 'artificial gamete formation' and 'fertilization' can be considered pseudo-proof. However, it should be noted that functionality does not necessarily mean that artificial gametes are genetically and epigenetically equal to normal gametes. Within our end-point 'artificial gamete formation', several forms of proof were accepted (i.e. DNA content analyses, presence of markers and, for oocytes, polar body extrusion). It is important to note that in general, DNA content analyses are seen as more reliable than the presence of markers, and oocyte polar body extrusion (a form of morphological evidence) is seen as least reliable. Moreover, recent evidence suggests the production of a polar body is dissociable from the chromosomal events of meiosis 124 , stressing the importance of discerning between the different levels of proof of gamete formation presented by the papers included in this review, varying between polar body extrusion and the birth of offspring. Furthermore, excluding intermediate end-points (e.g. the formation of primordial germ cells 125 ) resulted in the exclusion of interesting studies. Finally, the predefined end-points for artificial oocyte formation were less strict than those for artificial sperm formation in accordance with the natural differences between spermatogenesis and oogenesis, resulting in less robust evidence on artificial oocyte formation. For example, polar body extrusion was accepted as indication of artificial oocyte formation, whereas morphological evidence only was not accepted as indication of artificial sperm formation.
Fourth, frameworks had to be developed to structure the metasynthesis of our findings to ensure understandability for professionals who are not specialists in artificial gametes. This resulted in the need to use a priori defined start-and endpoints and to differentiate between all biologically plausible routes to create artificial gametes. However, excluding 'patient gametes' as a starting point prevented us from that addressing some interesting techniques (e.g. oocyte nuclear transfer, in which the nucleus of a patient's oocyte is transferred into an enucleated, younger, donor oocyte 46, 47 ). Moreover, excluding intermediate endpoints (e.g. the formation of primordial germ cells 125 ) resulted in the exclusion of other interesting studies. Finally, the predefined end-points for artificial oocyte formation were less strict than those for artificial sperm formation, in accordance with the natural differences between spermatogenesis and oogenesis, resulting in less robust evidence on artificial oocyte formation. For example, polar body extrusion was accepted as indication of artificial oocyte formation, whereas only morphological evidence (i.e. an elongated cell with a 'tail') was not accepted for sperm formation.
Fifth, this review was limited to describing effectiveness (gamete formation, fertilization, the birth of offspring) rather than efficiency and/or long-term safety, as the included studies focus on effectiveness.
Future preclinical research could contribute to safeguarding the following three dimensions of quality of healthcare defined by the Institute of Medicine: 'effectiveness' (i.e. providing services based on scientific knowledge in order to result in benefit), 'efficiency' (i.e. avoiding waste) and 'safety' (i.e. avoiding injuries to patients and their offspring 126 ). Currently, the main preclinical biological research focus is on the proof of principle (i.e. effectiveness) proven by its final test: the birth of viable offspring. For some groups of beneficiaries (e.g. gay men requiring artificial oocytes from males), however, more research on effectiveness still needs to be performed than for others (e.g. heterosexual couples with male infertility requiring artificial sperm from males). In our opinion, the focus of preclinical biological research should be on healthy offspring, rather than viable offspring, which is a combined measure of effectiveness and safety. Only a minority of studies assessed safety in terms of genetic and epigenetic normality of artificial gametes, or the epigenetic status and (long-term) health of offspring derived from them. Some studies (e.g. 51, 88, 113 ) did describe (ab)normal growth, the capability to reproduce and/or the life expectancy of offspring. Obviously, clinical application will require rigorous production of the appropriate safety data, for which we recommend setting up long-term follow-up of offspring, first in animals and later in children.
Regarding efficiency of the biologically plausible methods, little has been reported (e.g. how many attempts were required to end up with one artificial gamete or offspring). Before clinical application, efficiency requires extensive research. After all, for clinical purposes, it is crucial that treatment options fall within humanly reasonable scales relating to, for example, the number of GSCs needed or the number of donor oocytes required for one pregnancy.
Based on reviewing the biological evidence, we identified the different routes to generate artificial gametes, and their progress. However, there is insufficient evidence to recommend focusing on one or more superior route(s), as all routes are at the forefront of biology (i.e. they challenge our understanding and technical possibilities).
CONCLUSION
Although they are currently still in an experimental stage, and the time frame until possible clinical application is difficult to predict, studies on artificial gametes seem to be progressing steadily towards possible future clinical application. The increasing amount of biological studies will point us towards the safest and most efficient method to create artificial gametes. Deciding to introduce artificial gametes in clinical practice, however, requires a point of view that goes beyond biologic parameters. First, artificial gametes could change the field of MAR dramatically by discarding the entire concept of infertility, and potentially allowing new groups of patients (e.g. heterosexual couples without functional gametes, post-menopausal women and gay couples) to have genetically related children. Second, we are unable to acquire informed consent from the children that will be conceived. Therefore, to prevent premature implementation of artificial gametes, driven by profit and patients' demands, as with ICSI and PGD [16] [17] [18] [19] [20] 23 , all stakeholders should be involved in deciding on the timing and conditions (including, but not limited to, safety and efficiency) of any future implementation into clinical practice.
